antibody

MOUSE ANTI MDM2

MBS215152

0.02 mg

195 USD

monoclonal

mouse

nonconjugated

SMP14

Antibody

MOUSE ANTI MDM2

MDM2

E3 ubiquitin-protein ligase Mdm2 isoform h; E3 ubiquitin-protein ligase Mdm2; E3 ubiquitin-protein ligase Mdm2; MDM2 oncogene, E3 ubiquitin protein ligase; Mdm2, p53 E3 ubiquitin protein ligase homolog; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; double minute 2, human homolog of; p53-binding protein; oncoprotein Mdm2; MDM2 proto-oncogene, E3 ubiquitin protein ligase; Double minute 2 protein; Hdm2; Oncoprotein Mdm2; p53-binding protein Mdm2

MDM2

MDM2; MDM2; HDMX; hdm2; ACTFS; Hdm2

MDM2_HUMAN

Monoclonal

IgG1

SMP14

Mouse

442

Purified. Purified IgG - liquid

IgG concentration 1.0 mg/ml

Store at 4 degree C or at -20 degree C if preferred. This product should be stored undiluted. Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. Shelf Life: 18 months from date of despatch.

Immunohistology Frozen, Immunohistology Paraffin*, Immunohistology Resin (RE)

Immunohistology - Paraffin: Minimum Dilution: 1/200; Maximum Dilution: 1/500; Application Note: This product requires antigen retrieval using heat treatment prior to staining of paraffin sections. EDTA pH8.0 is recommended for this purpose.

Perservative Stabilisers: 0.09% Sodium Azide. Preparation: Purified IgG prepared by affinity chromatography on Protein G

Immunogen: Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2. Histology Positive Control Tissue: Breast carcinoma. Fusion Partners: Spleen cells from immunised BALB/c mice were fused with cells of the mouse X63Ag8.653 myeloma cell line. Buffer Solution: Phosphate buffered saline. Target Species: Human

Mouse anti MDM2 antibody, clone SMP14 recognizes the 90kDa MDM2 protein, which forms a complex with p53 leading to p53 inhibition. MDM2 also acts to stimulate cell proliferation via its induction of transcription factors such as E2F1 and DPI. MDM2 is over expressed in a range of human malignancies, including soft tissue sarcomas, breast cancer and bladder cancer.

223890205

NP_001138811.1

NM_001145339.2

Q00987

55,991 Da

AKT Phosphorylates Targets In The Cytosol Pathway (106475); Adaptive Immune System Pathway (366160); Androgen Receptor Signaling Pathway (198806); Apoptosis Pathway (198797); Aurora A Signaling Pathway (137925); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cell Cycle Pathway (530733); Cell Cycle Checkpoints Pathway (105739); Cell Cycle Pathway (198811)

This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013]

MDM2: a ubiquitin ligase for p53, plays a central role in regulation of the stability of p53 via Akt-mediated MDM2 phosphorylation. Phosphorylation of MDM2 increases its interaction with p300, providing a platform to allow the assembly of the protein complex necessary for MDM2-mediated ubiquitination and degradation of p53. Phosphorylation of MDM2 also blocks its binding to p19ARF, increasing the degradation of p53. Facilitates the nuclear export of p53 and targets it for proteasome-mediated proteolysis. Eight alternatively spliced isoforms have been reported. Protein type: Ubiquitin ligase; Ligase; Inhibitor; Ubiquitin conjugating system; Oncoprotein; Nucleolus; EC 6.3.2.-; EC 6.3.2.19. Chromosomal Location of Human Ortholog: 12q14.3-q15. Cellular Component: nucleoplasm; nuclear body; protein complex; cytoplasm; nucleolus; plasma membrane; synapse; cytosol; nucleus. Molecular Function: identical protein binding; peroxisome proliferator activated receptor binding; protein binding; enzyme binding; zinc ion binding; p53 binding; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; ligase activity. Biological Process: nerve growth factor receptor signaling pathway; viral reproduction; protein ubiquitination during ubiquitin-dependent protein catabolic process; response to morphine; protein ubiquitination; negative regulation of caspase activity; negative regulation of transcription from RNA polymerase II promoter; positive regulation of mitotic cell cycle; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; response to carbohydrate stimulus; positive regulation of protein export from nucleus; response to antibiotic; negative regulation of DNA damage response, signal transduction by p53 class mediator; synaptic transmission; response to magnesium ion; establishment of protein localization; peptidyl-lysine modification; positive regulation of cell proliferation; protein complex assembly; response to iron ion; response to drug; epidermal growth factor receptor signaling pathway; traversing start control point of mitotic cell cycle; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; protein destabilization; response to ether; response to cocaine; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; innate immune response; regulation of protein catabolic process; negative regulation of transcription, DNA-dependent. Disease: Accelerated Tumor Formation, Susceptibility To

0.02 mg

195 USD